Crestline Management’s Sight Sciences SGHT Stock Holding History

Crestline Management’s Portfolio SGHT Stock Details SGHT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-56,811	Closed	-$998K	–	326
2021 Q4	$998K	Buy	+56,811	New	+$1.25M	0.07%	143

Other funds holding SGHT

DCP

D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Crestline Management's SGHT Position: Q1 2022 in Review

Crestline Management sold out of Sight Sciences (SGHT) in Q1 2022, closing a stake of 56,811 shares — an estimated $998K sold.

Crestline Management first reported a position in SGHT in Q4 2021 and held it in 1 quarter. The position peaked at $998K in Q4 2021. 66 funds tracked by Wall St. Rank hold SGHT as of Q1 2022.

Crestline Management reported no remaining Sight Sciences position as of Q1 2022 after selling out during the quarter.
Crestline Management sold 56,811 Sight Sciences shares in Q1 2022, an estimated $998K.
Crestline Management first reported a position in Sight Sciences in Q4 2021 and held it in 1 quarter.
Crestline Management's Sight Sciences position peaked at $998K in Q4 2021.
66 funds tracked by Wall St. Rank held Sight Sciences as of Q1 2022.

Based on Crestline Management's 13F filing for Q1 2022, filed 16 May 2022.